SCHEMBL5376747

SCHEMBL5376747

Cc1ccc(S(=O)(=O)Nc2ccc(SCc3ccc(C(C)(C)C)cc3)cc2)cc1C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.54
PTPN5 P54829 1/20 0.52
CASP6 P55212 1/20 0.48
PABPC1 P11940 1/20 0.46
GHSR Q92847 1/20 0.46
ALDH1A1 P00352 5/20 0.46
MEN1 O00255 2/20 0.46
MAPT P10636 2/20 0.46
KMT2A Q03164 2/20 0.46
UQCRB P14927 1/20 0.46
GFER P55789 1/20 0.45
MCL1 Q07820 1/20 0.45
BCL2A1 Q16548 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
LMNA P02545 1/20 0.45
HTT P42858 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
HDAC3 O15379 2/20 0.45
HDAC11 Q96DB2 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5371856 0.91 POLB (0.53) POLBCASP6PABPC1ALDH1A1MEN1
Cp-778875 SCHEMBL1600965 0.90 POLB (0.58) POLBCASP6PABPC1ALDH1A1MEN1
SCHEMBL5386741 0.88 POLB (0.56) POLBCASP6PABPC1ALDH1A1MAPT
SCHEMBL5388054 0.88 POLB (0.56) POLBCASP6PABPC1ALDH1A1MEN1
SCHEMBL14437715 0.88 POLB (0.56) POLBCASP6PABPC1ALDH1A1MEN1
SCHEMBL5375209 0.88 POLB (0.58) POLBCASP6PABPC1ALDH1A1MEN1
SCHEMBL5369948 0.87 POLB (0.53) POLBCASP6PABPC1ALDH1A1MEN1
SCHEMBL5373188 0.87 POLB (0.55) POLBCASP6PABPC1ALDH1A1MEN1
SCHEMBL5375322 0.86 POLB (0.54) POLBCASP6PABPC1GHSRALDH1A1
SCHEMBL5318260 0.86 POLB (0.48) POLBPTPN5PABPC1GHSRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1725524-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS Pfizer Products Incorporated (US) 2006-11-29 EP claimed
US-20060258723-A1 Substituted Heteroaryl- and Phenylsulfamoyl Compounds PFIZER INC 2006-11-16 US claimed
US-20050228015-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER INC 2005-10-13 US claimed
WO-2005092845-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PFIZER PRODUCTS INC. (US) 2005-10-06 WO claimed
US-7262318-B2 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER, INC. (US) 2007-08-28 US disclosed
US-7262318-B2 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER, INC. (US) 2007-08-28 US disclosed
US-7262318-B2 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER, INC. (US) 2007-08-28 US disclosed
EP-1725524-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS Pfizer Products Incorporated (US) 2006-11-29 EP disclosed
US-20060258723-A1 Substituted Heteroaryl- and Phenylsulfamoyl Compounds PFIZER INC 2006-11-16 US disclosed
US-20050228015-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER INC 2005-10-13 US disclosed
WO-2005092845-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PFIZER PRODUCTS INC. (US) 2005-10-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050228015-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PPARA, PPARG, PPARD POLB 1807/4885PTPN5 2304/4885CASP6 3606/4885
US-20060258723-A1 Substituted Heteroaryl- and Phenylsulfamoyl Compounds PPARG, PPARA, PPARD POLB 2006/4885PTPN5 2417/4885CASP6 3811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.